Focal segmental glomerulosclerosis (FSGS) is a well-defined histologic pattern of injury characterized by sclerosis, hyalinosis, foam-cell infiltration, vacuolization of podocytes, and podocyte precursor proliferation between glomeruli tuft and Bowman’s capsule. It is “focal” in that only some glomeruli are affected and “segmental” where only a portion of the affected glomerulus is sclerosed.FSGS may be found either as primary or secondary forms. Primary FSGS sometimes has no identifiable cause or known etiology and linked to genetic mutations in podocyte-specific proteins, while secondary FSGS might include familial/genetic forms, virus-associated forms, drug-induced forms, and forms mediated by adaptive structural-functional response.

 

The clinical features of FSGS include peripheral edema, marked proteinuria, hypertension, hypoalbuminemia, hyperlipidemia, and progressive loss of renal function. The pathogenesis of FSGS is very complex, mostly podocyte injury and parietal epithelial cells lining Bowman’s capsule play a central role in the disease progression. FSGS is classified as collapsing, tip, cellular, perihilar, and not otherwise specified variants according to the location and character of the sclerotic lesion (Columbia Classification).

 

 

 

 

Reques for :- free sample page

 

 

The DelveInsight Focal Segmental Glomerulosclerosis (FSGS) epidemiology report gives a thorough understanding of the Focal Segmental Glomerulosclerosis (FSGS) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Focal Segmental Glomerulosclerosis (FSGS) in the US, Europe, and Japan. The report covers the detailed information of the Focal Segmental Glomerulosclerosis (FSGS) epidemiology scenario in seven major countries (US, EU5, and Japan).

 

 

The Focal Segmental Glomerulosclerosis (FSGS) epidemiology covered in the report provides historical as well as forecasted Focal Segmental Glomerulosclerosis (FSGS) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

The DelveInsight Focal Segmental Glomerulosclerosis (FSGS) report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

 Report Key facts:- 

1.  Age plays important role in the prevalence of FSGS. As per DelveInsight estimates, there were 4,306 cases of children with FSGS, while adults contribute 8,613 cases of FSGS in 2017 for Germany.

2. In 2017, there were 45,852 prevalent cases of FSGS in males and 34,731 cases in females and as per analyst assessments, the overall cases of FSGS in both the genders is subjected to increase in the coming years in 7MM.

 

“According to DelveInsight’s analysis, Male cases of FSGS are more prominent in comparison to Female”

Key companies are working on FSGS are given below:-

1. Retrophin Pharma Co

2. Dimerix Pharma Co. 

3.Aurinia Pharmaceuticals.

Name of drugs covered that are given below:- 

1. Sparsentan
2. DMX-200
3. Voclosporin

Table of contents

1. Key Insights 

2. Executive Summary of Focal Segmental Glomerulosclerosis (FSGS)

3. Focal Segmental Glomerulosclerosis (FSGS): Disease Background and Overview

4. Patient Journey

5. Epidemiology and Patient Population

6. Treatment Algorithm, Current Treatment, and Medical Practices

6.1. Focal Segmental Glomerulosclerosis (FSGS) Treatment and Management

6.2. Focal Segmental Glomerulosclerosis (FSGS) Treatment Algorithm

7. KOL Views

8. Unmet Needs

9.  Appendix

9.1. Bibliography

9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

Why should you buy this report?

• The Focal Segmental Glomerulosclerosis (FSGS) Epidemiology report will allow the user to –
• Develop business strategies by understanding the trends shaping and driving the global Focal Segmental Glomerulosclerosis (FSGS) market
• Quantify patient populations in the global Focal Segmental Glomerulosclerosis (FSGS) market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Focal Segmental Glomerulosclerosis (FSGS) therapeutics in each of the markets covered
• Understand the magnitude of Focal Segmental Glomerulosclerosis (FSGS) population by its epidemiology
• The Focal Segmental Glomerulosclerosis (FSGS) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

 Related Reports :- 

1. Focal Segmental Glomerulosclerosis (FSGS)- Market Insight, Epidemiology and Market Forecast -2030

2. Focal Segmental Glomerulosclerosis (FSGS) – Pipeline Insights, 2020